Literature DB >> 12510152

Apoptotic action of estrogen.

R X-D Song1, R J Santen.   

Abstract

Estrogen as a mitogen stimulates cell proliferation and prevents cell death in many cell types. In patients, estrogen is known to stimulate breast and uterus cancer development. Ironically, high doses of estrogen can induce regression of hormone-dependent breast cancer in postmenopausal women. The comprehensive mechanism by which estrogen induces tumor recession in breast cancer is still unknown, but activation of the Fas/FasL pathways plays a key role in this process. Laboratory studies show that the apoptotic action of estrogen is the major factor leading to cell number decreases in several cell types. The effects of estrogen are estrogen-receptor dependent. In this mini review, we will focus on the latest findings regarding estrogen apoptotic effects in several cell models, including breast cancer cells, and summarize the possible mechanisms involved in these estrogen mediated processes. New potential implications for the pharmacological control of breast cancer with estrogen in post-menopausal women are also discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12510152     DOI: 10.1023/a:1021649019025

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  29 in total

1.  Gender influences the response to experimental silica-induced lung fibrosis in mice.

Authors:  David M Brass; Sean P McGee; Mary K Dunkel; Sarah M Reilly; Jacob M Tobolewski; Tara Sabo-Attwood; Cheryl L Fattman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-08-20       Impact factor: 5.464

2.  CASP8 polymorphisms contribute to cancer susceptibility: evidence from a meta-analysis of 23 publications with 55 individual studies.

Authors:  Ming Yin; Jingrong Yan; Sheng Wei; Qingyi Wei
Journal:  Carcinogenesis       Date:  2010-02-22       Impact factor: 4.944

3.  Estrogens up-regulate the Fas/FasL apoptotic pathway in lactotropes.

Authors:  G Jaita; M Candolfi; V Zaldivar; S Zárate; L Ferrari; D Pisera; M G Castro; A Seilicovich
Journal:  Endocrinology       Date:  2005-08-11       Impact factor: 4.736

4.  Tumorigenicity of MCF-7 human breast cancer cells lacking the p38α mitogen-activated protein kinase.

Authors:  Rhone A Mendoza; Emily E Moody; Marlene I Enriquez; Sylvia M Mejia; Gudmundur Thordarson
Journal:  J Endocrinol       Date:  2010-10-25       Impact factor: 4.286

5.  Uterine epithelial estrogen receptor α is dispensable for proliferation but essential for complete biological and biochemical responses.

Authors:  Wipawee Winuthayanon; Sylvia C Hewitt; Grant D Orvis; Richard R Behringer; Kenneth S Korach
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

6.  NF-kappaB suppression provokes the sensitization of hormone-resistant breast cancer cells to estrogen apoptosis.

Authors:  Y S Lobanova; A M Scherbakov; V A Shatskaya; V A Evteev; M A Krasil'nikov
Journal:  Mol Cell Biochem       Date:  2008-12-20       Impact factor: 3.396

Review 7.  The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer.

Authors:  V Craig Jordan
Journal:  Endocr Relat Cancer       Date:  2014-10-22       Impact factor: 5.678

8.  Estrogen stimulates proliferation and differentiation of neural stem/progenitor cells through different signal transduction pathways.

Authors:  Makiko Okada; Akihisa Makino; Mitsunari Nakajima; Satoshi Okuyama; Shoei Furukawa; Yoshiko Furukawa
Journal:  Int J Mol Sci       Date:  2010-10-22       Impact factor: 5.923

9.  Unique roles of p160 coactivators for regulation of breast cancer cell proliferation and estrogen receptor-alpha transcriptional activity.

Authors:  Sudipan Karmakar; Estrella A Foster; Carolyn L Smith
Journal:  Endocrinology       Date:  2008-12-18       Impact factor: 4.736

10.  Antiproliferative effect of exemestane in lung cancer cells.

Authors:  Angelos Koutras; Efstathia Giannopoulou; Ismini Kritikou; Anna Antonacopoulou; T R Jeffry Evans; Athanasios G Papavassiliou; Haralabos Kalofonos
Journal:  Mol Cancer       Date:  2009-11-24       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.